All In Biotech

Drug Trial Radar · NCT04988295

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 776 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

776

Actual

Start

Nov 17, 2021

Primary completion

Jul 10, 2023

Study completion Jul 3, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • LazertinibDrug

    Lazertinib will be administered orally.

  • AmivantamabDrug

    Amivantamab will be administered as an IV infusion.

  • PemetrexedDrug

    Pemetrexed will be administered as an IV infusion.

  • CarboplatinDrug

    Carboplatin will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)
  2. Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: up to 4 years 10 months
  3. Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central ReviewTime frame: Up to 4 years 10 months

Locations

249 sites in 29 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, PC

    Mobile, Alabama

  • Arizona Oncology Associates

    Tucson, Arizona

  • City of Hope

    Duarte, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center

    Fort Lauderdale, Florida

  • University Cancer And Blood Center LLC

    Athens, Georgia

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Nebraska Cancer Specialists

    Grand Island, Nebraska

  • Astera Cancer Care

    East Brunswick, New Jersey

  • TriHealth Network

    Cincinnati, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • Kaiser Permanente Northwest

    Portland, Oregon

  • Alliance Cancer Specialists

    Horsham, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Baptist Cancer Center

    Memphis, Tennessee

  • Texas Oncology-Medical City Dallas

    Dallas, Texas

  • Texas Oncology Baylor Charles A Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology

    Grapevine, Texas

  • Oncology Consultants Texas

    Houston, Texas

  • Texas Oncology - Northeast

    Longview, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Blue Ridge Cancer Care

    Wytheville, Virginia

  • NorthWest Medical Specialties, PLLC

    Puyallup, Washington

  • Compass Oncology

    Vancouver, Washington

  • CINME Centro de Investigaciones Metabolicas

    Caba, Argentina

  • IADT Instituto Argentino de Diagnostico y Tratamiento

    CABA, Argentina

  • Centro Medico Fleischer

    CABA, Argentina

  • CEMIC (Centro de Educación Médica e Investigaciones Clínicas)

    CABA, Argentina

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina

  • Hospital Privado Universitario De Cordoba

    Córdoba, Argentina

  • Hospital Privado de la Comunidad

    Mar del Plata, Argentina

  • Clínica Viedma

    Viedma, Argentina

  • Grand Hopital De Charleroi Site Les Viviers

    Charleroi, Belgium

  • UZA

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, Belgium

Showing 40 of 249 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.